Radiotheranostics in oncology: current challenges and emerging opportunities
Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …
assessment in patients with cancer; however, as clinicians increasingly seek to …
Molecular imaging in oncology: Current impact and future directions
The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …
Molecular Imaging, as the visualization, characterization, and measurement of biological …
The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance …
Background Multiparametric magnetic resonance imaging (MRI) is validated for the
detection of clinically significant prostate cancer (csPCa), although patients with …
detection of clinically significant prostate cancer (csPCa), although patients with …
Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter …
TA Hope, M Eiber, WR Armstrong, R Juarez… - JAMA …, 2021 - jamanetwork.com
Importance The presence of pelvic nodal metastases at radical prostatectomy is associated
with biochemical recurrence after prostatectomy. Objective To assess the accuracy of …
with biochemical recurrence after prostatectomy. Objective To assess the accuracy of …
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective …
Background Conventional imaging using CT and bone scan has insufficient sensitivity when
staging men with high-risk localised prostate cancer. We aimed to investigate whether novel …
staging men with high-risk localised prostate cancer. We aimed to investigate whether novel …
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …
E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET
Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …
[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)
Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …
tomography (PET) is emerging to become a reference imaging tool for the staging and …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm …
Summary Background National Comprehensive Cancer Network guidelines consider 18 F-
fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical …
fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical …